Dominika Kuzmiuk

Ms. Dominika Kuzmiuk

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2025 in Annals of Medicine
Verified
Journal Article
Open access
DŻDominika Żyła
Dominika Żyła
DKDominika Kuzmiuk
Dominika Kuzmiuk
MRMartyna Rynkowska
Martyna Rynkowska
MSMałgorzata Satora
Małgorzata Satora
KKKrzysztof Jerzy Kułak
Krzysztof Jerzy Kułak
RTRafał Tarkowski
Rafał Tarkowski
Progestins are a group of substances with a wide range of applications. They are classified into pregnanes, estranes, and gonanes, and further divided into four generations based on their testosterone (TE) or progesterone (P4) origin. This study reviews the existing literature on the clinical use of progestins. A literature review was conducted by PubMed, Google Scholar, Scopus and ClinicalTrials. The following search terms and their combinations were used when reviewing the aforementioned databases: (progestogen OR progestogens OR progestin OR progestins) AND (women OR woman OR men OR man OR adult). The analyzed publications about progestins were dated from 2005 to 2024. Progestins are used in both women and men, either alone (progestin-only contraception, POC) or combined with other substances (combined hormonal contraception, CHC). They are primarily used for contraception but also offer therapeutic benefits for conditions like abnormal uterine bleeding, endometriosis, secondary amenorrhea, infertility, and endometrial hyperplasia. In women with a uterus, balancing progestin with estrogen is crucial to prevent endometrial cancer. Progestins are also used in menopausal hormone therapy (MHT) to alleviate menopausal symptoms and can help prevent premature deliveries. Ongoing clinical trials are exploring their broader potential. Progestins have diverse therapeutic uses, with promising applications in various diseases. However, off-label use may present legal risks for healthcare providers, highlighting the need for clearer guidelines, particularly in non-gynecological treatments.

Verified
Journal Article
Open access
PDF file
MKMaria Kiełbus
Maria Kiełbus
DKDominika Kuzmiuk
Dominika Kuzmiuk
ASAleksandra Magdalena Skrzyniarz
Aleksandra Magdalena Skrzyniarz
AZAleksandra Zynkowska
Aleksandra Zynkowska
JDJoanna Dolar-Szczasny
Joanna Dolar-Szczasny
Robert RejdakRobert Rejdak
Robert Rejdak
The study of the aqueous humor (AH) plays a key role in understanding the pathophysiology of glaucoma. The AH provides nutrition, maintains the appropriate intraocular pressure, and provides important information about the mechanisms of the disease. The development of modern technologies has allowed the use of more accurate analytical methods, which has proven to be a key factor in determining the changes occurring in the proteome of the aqueous humor of glaucoma patients. Recently, researchers have observed changes in the levels of proteins associated with inflammation, oxidative stress, the complement system, and extracellular matrix remodeling. They have also shown that these changes may be variable for different types of glaucoma. The objective of this review is to collect and summarize the current knowledge on the potential biomarkers and pathomechanisms involved in the pathogenesis of glaucoma. We hope that our review will contribute to the improvement of current diagnostic methods in this illness and, through a better understanding of the changes occurring during the progression of the disease, will enable the development of more effective preventive and therapeutic strategies in the future.

Verified
Journal Article
Open access
PDF file
KKKarolina Aleksandra Klusek
Karolina Aleksandra Klusek
MKMagdalena Kijowska
Magdalena Kijowska
MKMaria Kiełbus
Maria Kiełbus
JSJulia Sławińska
Julia Sławińska
DKDominika Kuzmiuk
Dominika Kuzmiuk
JDJoanna Dolar-Szczasny
Joanna Dolar-Szczasny
There is growing interest in the use of natural plant-derived compounds, such as polyphenols (including curcumin), flavonoids, silymarin, anthocyanins, lutein, and zeaxanthin, for the treatment of age-related macular degeneration (AMD). These substances exhibit antioxidant, anti-inflammatory, and protective effects on retinal cells, contributing to the preservation of retinal integrity by modulating the key pathogenic mechanisms of AMD, including oxidative stress, chronic inflammation, and pathological neovascularization. Consequently, they hold potential to support conventional therapeutic approaches and slow disease progression. Current studies highlight their promising role as adjunctive agents in AMD management. This literature review provides a comprehensive analysis of the potential role of the aforementioned natural plant-derived compounds in the prevention and supportive treatment of age-related macular degeneration. It also discusses their natural sources, modes of administration and supplementation, and highlights the importance of a nutrient-rich diet as a key factor in maintaining ocular health. Furthermore, the review synthesizes current scientific knowledge on the ability of natural antioxidants to slow the progression of AMD and outlines future research directions aimed at improving diagnostic methods and developing more effective preventive and therapeutic strategies.

23 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JDJoanna Danio
Joanna Danio
KPKatarzyna Procajło
Katarzyna Procajło
PSPrzemysław Szostak
Przemysław Szostak
MRMartyna Rynkowska
Martyna Rynkowska
SMSylwia Maj
Sylwia Maj
DSDominika Sidor
Dominika Sidor
Introduction and objective: Chronic stress is a serious and growing health problem associated with numerous physical and mental disorders. Traditional stress management methods often fail to deliver the expected results, increasing interest in natural alternatives. The aim of this paper is to review current data on adaptogens – Withania somnifera (ashwagandha), Rhodiola rosea and Schisandra chinensis– with particular emphasis on their stress-reducing properties. Brief description of the state of knowledge: Chronic stress contributes to various health issues, both physical and psychological. Adaptogens such as Withania somnifera, Rhodiola rosea and Schisandra chinensis exhibit stress-reducing effects by modulating the hypothalamic-pituitary-adrenal (HPA) axis and neurotransmitter systems. Clinical studies confirm their good tolerability however, variability in product composition complicates the assessment of their efficacy. Further standardized and long-term studies are needed to confirm their benefits and safety. Summary: Chronic stress remains a widespread health challenge linked to diverse disorders. Since conventional methods often prove insufficient, interest in plant-based adaptogens is increasing. These substances not only alleviate symptoms but also regulate key biological systems involved in the stress response. Withania somnifera, Rhodiola rosea and Schisandra chinensis show promising results, and other adaptogens may support comprehensive stress management. Future research should focus on long-term safety, clarification of mechanisms of action, and standardization of formulations. Adaptogens bridge traditional knowledge and modern science, offering natural support for mental health and well-being in today’s stressful environment.

29 April 2026 in Environmental Medicine
Verified
Journal Article
Open access
PDF file
DKDominika Kuzmiuk
Dominika Kuzmiuk
DSDominika Sidor
Dominika Sidor
MRMartyna Rynkowska
Martyna Rynkowska
SMSylwia Maj
Sylwia Maj
KPKatarzyna Procajło
Katarzyna Procajło
JDJoanna Marta Danio
Joanna Marta Danio
Introduction and objective: Vegetarian and vegan diets are increasingly adopted for health, environmental, and ethical reasons. These dietary patterns are rich in antioxidants, such as lutein and zeaxanthin, which may support retinal health. However, exclusion of animal-derived foods may...

7 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
WSWiktoria Sikorska
Wiktoria Sikorska
ASAlbert Sikorski
Albert Sikorski
SMSylwia Maj
Sylwia Maj
KPKatarzyna Procajło
Katarzyna Procajło
DKDominika Kuzmiuk
Dominika Kuzmiuk
MMMaciej Karol Marek
Maciej Karol Marek
Aim: This review analyses the role of lutein and zeaxanthin in preventing and treating age-related eye diseases, including age-related macular degeneration (AMD), cataracts, and glaucoma. Furthermore, it explores their critical applications in pediatric populations, pregnant women, and the broader socio-economic implications of visual impairment in the digital age. Materials and Methods: The review included scientific articles published from 2000 to 2025, sourced in English from PubMed and Scopus, using keywords such as lutein, zeaxanthin, AMD, cataract, glaucoma, retina, microbiome, and supplementation. The selection followed PRISMA protocols and AMSTAR 2 guidelines, incorporating clinical trials (RCTs), preclinical studies, and systematic reviews. Results: Lutein and zeaxanthin accumulate in the macula, neutralizing reactive oxygen species via the Nrf2 pathway and shielding against UV and digital blue light. Supplementation reduces the risk of AMD progression by 18–26%, cortical cataracts by 20–25%, and glaucoma by 15–20%. Advanced delivery methods, such as PLGA and lipid-based nanoparticles, increase carotenoid bioavailability by up to 40%. In preterm infants, supplementation reduces the risk of retinopathy by 50%. In children, it protects against screen-related photic damage, while in older adults, it boosts cognitive function by up to 12%. Conclusions: Lutein and zeaxanthin play a highly significant role in preventing age-related eye diseases and mitigating digital eye strain. Beyond individual clinical benefits, evidence-based, population-wide supplementation programs—enhanced by novel nanoparticle delivery systems and gut-microbiome modulation—can yield substantial socio-economic benefits by reducing the global burden of visual impairment. Future research must focus on large-scale RCTs to standardize dosing regimens.